Tag Archive for: Neuraxpharm

Neuraxpharm completes its presence in the Benelux by opening an affiliate in Brussels to cover Belgium and Luxembourg

/in

Belgium team to expand under Country Manager, Dr Pierre-Hervé Brun, providing CNS treatments to patients Brussels and Düsseldorf – January 24, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Belgium to cover Belgium and Luxembourg, completing its presence […]

Read more

Neuraxpharm expands into the Netherlands

/in

The CNS specialist continues its strong expansion course in Europe and increases its presence from two to 20 countries in just six years Naarden and Düsseldorf – December 7, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Netherlands. […]

Read more

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

/in

 The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD) Mataró, Barcelona (Spain) and Düsseldorf (Germany), November 10, 2022 – Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders and the Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company […]

Read more

Neuraxpharm expands its business in Southeast Europe

/in

Acquisition of Brain Therapeutics with operations in Greece, Cyprus and the Balkan countries Dusseldorf and Barcelona, March 8th, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces the expansion of its business in Southeast Europe through the acquisition of Brain Therapeutics, a CNS-focused marketing and distribution […]

Read more

Neuraxpharm provides business update on a transformational year

/in

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today provides a business update for the last twelve months. Following the rebranding of the company in October 2018 to Neuraxpharm from NuPharm Group, Neuraxpharm has made great strides to build a sustainable business in the past year, delivering […]

Read more